Currently, Paul A. Friedman is Chairman, President & Chief Executive Officer for Madrigal Pharmaceuticals, Inc. Dr. Friedman is also on the board of Incyte Corp. (former President, Chief Executive Officer & Director), Alexion Pharmaceuticals, Inc., Gliknik, Inc. and Prelude Therapeutics, Inc. and Member of American Society for Pharmacology & Experimental Therapeutic, Member of American Society for Biochemistry & Molecular Biology, Inc. and Member of American Society for Clinical Investigation.

In the past he was Director at Cerulean Pharma, Inc., President for DuPont Pharmaceuticals Research Laboratories, President-Research & Development at DuPont Merck Pharmaceutical Co., Senior Vice President at Merck Research Laboratories and Associate Professor at Harvard Medical School.

He received an undergraduate degree from Princeton University and a doctorate from Harvard Medical School.